Search Results

• • 44 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Androgen deprivation therapy induces vitamin K loss in men with prostate cancer.

  Author:Hisashi MatsushimaFrom:Biology and Medicine (Vol. 9, Issue 4) Peer-Reviewed

  July 1, 20173,057 words Report 1400LAbstract Bone strength is determined by bone mineral density (BMD) and bone quality. Bone fractures are serious adverse events in men receiving androgen deprivation therapy (ADT) for prostate cancer. Although it is...

• Osteoporosis: The connection to urologic health

  Author:Angela M. CheungFrom:Canadian Urological Association Journal (Vol. 8, Issue 7-8Suppl5) Peer-Reviewed

  July-August 20141,233 words Report 2050LAuthor(s): Angela M. Cheung, MD, PhD, FRCPC, CCD Introduction Osteoporotic fractures are common in men, particularly in men undergoing androgen deprivation therapy (ADT) for prostate cancer treatment. As outcomes...

• In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis

  Authors:Daniel L. Suzman and Emmanuel S. AntonarakisFrom:Oncology (Vol. 28, Issue 10) Peer-Reviewed

  Oct. 20141,187 words Report 1670LPRO Medical or surgical castration (also termed androgen deprivation therapy [ADT]) has been the mainstay of therapy for men with newly diagnosed metastatic prostate cancer. However, with the exception of the potential...

• Taking the first steps in establishing recommendations for testosterone monitoring in men with prostate cancer on androgen-deprivation therapy

  Author:Alvaro MoralesFrom:Canadian Urological Association Journal (Vol. 11, Issue 6) Peer-Reviewed

  June 20171,075 words Report 2040LThe paper by Shayegan et al in this issue of CUAJ represents an important initial step in establishing recommendations for hormonal monitoring in men with prostate cancer on androgen-deprivation therapy (ADT). As...

• A comparative study of the effects of medical versus surgical androgen deprivation therapy on health-related quality of life in patients with metastatic carcinoma prostate

  Authors:Prabhjot Singh, Tapan Agrawal, Siddharth Yadav, Brusabhanu Nayak, Amlesh Seth, and Prem DograFrom:Indian Journal of Cancer (Vol. 55, Issue 2) Peer-Reviewed

  April-June 20182,699 words Report 1540LByline: Prabhjot. Singh, Tapan. Agrawal, Siddharth. Yadav, Brusabhanu. Nayak, Amlesh. Seth, Prem. Dogra INTRODUCTION: Androgen deprivation therapy (ADT) is known to adversely affect the quality of life (QoL). One may...

• Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion

  Authors:Yang Yu, Qingyun Zhang, Chengzhong Ma, Xue Yang, Rui Lin, Hongxiang Zhang, et al.From:Stem Cell Research & Therapy (Vol. 9, Issue 1) Peer-Reviewed

  Sept. 26, 20185,530 words Report 1690LBackground Androgen deprivation (AD) as the first-line treatment for advanced prostate cancer (PCa) is insufficient for a long-term effect. Castration resistance remains the greatest obstacle in PCa clinical therapy....

• Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors

  Authors:Ruben Algarra, Mateo Hevia, Antonio Tienza, Imanol Merino, Javier Zudaire, Jose Enrique Robles, et al.From:Canadian Urological Association Journal (Vol. 8, Issue 5-6) Peer-Reviewed

  May-June 20144,311 words Report 1400LAuthor(s): Rubén Algarra, MD, Mateo Hevia, MD, Antonio Tienza, MD, Imanol Merino, MD, José María Velis, MD, Javier Zudaire, MD, José Enrique Robles, MD, Ignacio Pascual, MD Introduction In patients treated...

• Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-[kappa]B-mediated PTP1B expression

  Authors:I-Chen Yu, Hung-Yun Lin, Ning-Chun Liu, Janet D. Sparks, Shuyuan Yeh, Lei-Ya Fang, et al.From:Diabetes (Vol. 62, Issue 2) Peer-Reviewed

  Feb. 20135,819 words Report 1530LClinical investigations highlight the increased incidence of metabolic syndrome in prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT). Studies using global androgen receptor (AR) knockout mice...

• Letters to the editor

  Authors:Molly Stewart, Hannah Wilson, Paul Abel, and Syed Imran Ali ShahFrom:Urologic Nursing (Vol. 36, Issue 4) Peer-Reviewed

  July-August 20162,258 words Letter to the editor... 1780LTo the editor: In their article, "Skeletal Health Part 1: Overview of Bone Health and Management in the Cancer Setting," Turner et al. (2016) describe the potential risks to skeletal health arising from the use of...

• CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model

  Authors:Ruisong Ye, Min Pi, John V. Cox, Satoru K. Nishimoto, and L. Darryl QuarlesFrom:Journal of Experimental & Clinical Cancer Research (Vol. 36, Issue 1) Peer-Reviewed

  June 28, 20176,993 words Report 1600LBackground GPRC6A is implicated in the pathogenesis of prostate cancer, but its role remains uncertain because of a purported tolerant gene variant created by substitution of a K..Y polymorphism in the 3rd...

• Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study

  Authors:Jun Won Park, Jae Hyun Lee, Hyon Joung Cho, You-Jung Ha, Eun Ha Kang, Kichul Shin, et al.From:PLoS ONE (Vol. 13, Issue 12) Peer-Reviewed

  Dec. 17, 20185,379 words Report 1530LObjectives Although estrogenic modulation of serum urate levels is well-known, the androgenic effect on urate homeostasis remains controversial. We investigated the effect of androgen deprivation therapy (ADT) on...

• Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma

  Authors:Chi-Ho Lee, Gang Huang, Pak-Hei Chan, Jojo Hai, Chun-Yip Yeung, Carol Ho-Yi Fong, et al.From:PLoS ONE (Vol. 12, Issue 2) Peer-Reviewed

  Feb. 3, 20174,515 words Report 1790LObjective Androgen deprivation therapy (ADT) increases fracture risk in men with carcinoma of the prostate, but little is known about the fracture risk for different types of ADT. We studied the fracture risk amongst...

• What we've learned so far about ADT

  Author:Neil E. FleshnerFrom:Canadian Urological Association Journal (Vol. 8, Issue 7-8Suppl4) Peer-Reviewed

  July-August 2014454 words Report 1380LAuthor(s): Neil E. Fleshner, MPH, MD, FRCSC Although the use of androgen deprivation has been with us for over 60 years, we continue to learn more and more about the androgen axis, how best to suppress it, and how to...

• Optimal bone health management strategies in patients with prostate cancer

  Authors:Gagan Prakash and Gagan GautamFrom:Indian Journal of Urology (Vol. 29, Issue 2) Peer-Reviewed

  April-June 20137,633 words Report 1720LByline: Gagan. Prakash, Gagan. Gautam Bone health is affected in patients with prostate cancer, both by the disease and its treatment. Metastases to bone leads to pain, fractures, and spinal cord compression; bone...

• Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors

  Authors:Francisco J. Castro-Alonso, Jennifer Dominguez-Pineda, Guillermo Rosales-Sotomayor, Thomas W. Flaig, and Maria T. BourlonFrom:Oncology (Vol. 32, Issue 5) Peer-Reviewed

  May 20183,054 words Case study 1820LThe Case A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus (T2DM) treated with metformin, 500 mg BID. He was also overweight...

• A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS

  Authors:Liam Bourke, Rebecca Turner, Rosa Greasley, Eileen Sutton, Liz Steed, Dianna Smith, et al.From:PLoS ONE (Vol. 13, Issue 7) Peer-Reviewed

  July 5, 20185,096 words Author abstract, Rep... 1590LBackground National guidelines (NICE-CG175) recommended 12 weeks of supervised exercise training for men treated with androgen deprivation therapy (ADT) for prostate cancer to counter debilitating adverse effects of...

• Next-generation therapy for residual prostate cancer

  Authors:Raymond A Clarke and Barry J AllenFrom:Immunotherapy (Vol. 5, Issue 11) Peer-Reviewed

  Nov. 20134,735 words Report 1610LAuthor(s): Raymond A Clarke [*] 1 , Barry J Allen 2 KEYWORDS : [alpha]-therapy; actinium; adjuvant therapy; alpharadin; bismuth; prostate cancer therapy; PSMA; radioimmunotherapy; TAT Prostatectomy and...

• Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy

  Authors:Mohammadali Mohammadzadeh Rezaei, Mohammadhadi Mohammadzadeh Rezaei, Alireza Ghoreifi, and Behzad Feyzzadeh KerighFrom:Canadian Urological Association Journal (Vol. 10, Issue 9-10) Peer-Reviewed

  September-October 20164,473 words Report 1880LIntroduction: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is...

• Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy

  Authors:Shintaro Maru, Hideki Uchino, Takahiro Osawa, Satoshi Chiba, Gaku Mouri, and Ataru SazawaFrom:PLoS ONE (Vol. 13, Issue 5) Peer-Reviewed

  May 24, 20183,939 words Report 1460LPurpose Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with...

• Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.

  Authors:Jae-Uk Jeong, Taek-Keun Nam, Ju-Young Song, Mee Sun Yoon, Sung-Ja Ahn, Woong-Ki Chung, et al.From:PLoS ONE (Vol. 16, Issue 3) Peer-Reviewed

  Mar. 12, 20215,210 words Report 1500LIntroduction To determine the prognostic significance of long-term adjuvant androgen deprivation therapy (A-ADT) over 1 year in achieving undetectable levels of prostate-specific antigen (PSA) less than 0.001 ng/mL in...